NCT05544968 - CD30biAb-AATC for CD30+ Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

July 31, 2028

Conditions

Hodgkin DiseaseCD30-Positive Diffuse Large B-Cell LymphomaCD30+ Anaplastic Large Cell LymphomaCD30+ Pleomorphic Large T-Cell Cutaneous LymphomaCD30+ Immunoblastic Large T-Cell Cutaneous LymphomaLeukemiaLymphoma

Interventions

DRUG

anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC)

anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells

DRUG

GM-CSF

Hematopoietic agent that helps form white blood cells.

Trial Locations (1)

53226

Froedtert & the Medical College of Wisconsin, Milwaukee

All Listed Sponsors

lead

Medical College of Wisconsin

OTHER